Nauman
Pfizer and BioNTech also announced 100 percent efficacy for COVID-19 in South Africa, where variant B.1.351 is predominant. The data also confirmed the effectiveness in preventing severe forms of the disease, which has no doubt killed many millions.
According to the US Centers for Disease Control, the vaccination is also 100% effective in preventing severe cases, but only 95.3 percent effective if we are to follow the definition of the US Food and Drug Administration.
They claim to have evaluated the data from over 44,000 participants aged 16 and older, including 12,000 participants who had a second dose of the shot. The efficacy was 91.3 percent between seven days to six months after the second dose.
Pfizer’s CEO Albert Bourla told the press: “These data confirm the vaccine’s decent efficacy and safety profile, so we’ll be submitting a Biologics License Application soon.”
The South African study involved 800 participants. Only nine cases of COVID-19 appeared in the placebo group. Six of them were confirmed to be the B.1.351 lineage of the disease, which caused concern when it first surfaced as vaccines were not designed to prevent this mutation.
The clinical trial is critical to confirming that a vaccine can effectively protect current circulating variants and reach herd immunity, which will help end this pandemic in the long run. Added Dr. Ugur Sahin, CEO, and Co-founder of BioNTech.
The new results from Public Health Scotland support the likelihood that this vaccine is safe and effective, which is based on previously published data as well as general statistics. They showed that the hospitalization rate was reduced by 85 percent when only the first round of the medicine was given, compared to the general population.
